Pipeline
Precision immunotherapies against the entire universe of intracellular antigens
Peptide:HLA targets are found on all tumor types and several major auto-immune and infectious diseases. By exploiting antibody display technologies and advanced AI, we are building a diverse pipeline of best-in-class therapies engineered to have maximum potency with minimal toxicity.
Program
Indications
Differentiator
Discovery
Lead optimization
IND-enabling
ONCOLOGY
Neoantigen
IM810
P53 R175H
Breast, colon, pancreatic
Single digit nM affinity
Best-in-class specificity
IM41X
FLT3 D835Y
Acute Myeloid Leukaemia
First-in-class therapy
Best-in-class specificity
Shared
IM61X
undisclosed
Solid tumors
Novel target - checkpoint resistant tumors
IM62X
undisclosed
Solid tumors
Novel target - checkpoint resistant tumors
Our approach to peptide:HLA targeting
The Imuno TACTICS discovery platform allows us to obtain full control over how these therapies recognise and destroy diseased tissue. Already from the earliest stages of development, we can tune antibodies for both affinity and specificity, enabling us to develop highly potent yet safe therapies.
